Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
David Wang · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · 2024 · $827,865 — Summary: Specific aim 1: To develop in vitro 2D neuronal and 3D brain organoid models derived from human adult peripheral CD34+ cells to study neural development and degeneration and infectious diseases involving human brain. Using the brain-on-the-chip microfluidic culture, we worked on 3D brain …
Elizabeth Ottinger · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $125,000 — TDB has performed a number of repurposing screening efforts and the IND-directed development of GS-441524. The latter included drug metabolism and pharmacokinetic (PK) studies, human PK modeling, toxicology studies, drug product manufacture and formulation studies. TDB scientists are also contributi…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $496,575 — We are developing parainfluenza virus- and pneumovirus-vectored vaccines for intranasal immunization against SARS-CoV-2. These viral vectors are designed to be highly attenuated in humans. They replicate to low levels in the superficial layers of the respiratory epithelium, and are optimized to indu…
Elodie Ghedin · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $812,851 — The major aspects of this project involve characterizing SARS-CoV-2 genetic diversity and microbial communities in the respiratory tract during infection. This involves analyzing samples from COVID-19 positive subjects, and from model animal infections. As part of this project we tackle different ty…
BRIAN KELSALL · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $10,914 — Demonstrating where SARS-CoV-2 infects and replicates in intestinal epithelium in vivo has been difficult to demonstrate conclusively. Therefore, we stained limited intestinal tissues from infected human autopsy samples for SARS-CoV2 both by immunofluorescence using antibodies to the SARS-CoV2 spik…
Pamela Schwartzberg · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $327,273 — Peripheral blood, tonsil tissues, and adenoid tissues were obtained from 110 children who underwent tonsillectomy at Children's National Hospital from late 2020 to 2021 with the goal of: 1) evaluating the prevalence of prior COVID-19 and epidemiologic risk factors for infection; 2) evaluating the na…
Carole Bewley · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $621,127 — The long-term goals of our project "HIV Neutralization Inhibitors: Engineering, characterization, and functions" are to identify and engineer protein and small molecule therapeutics, probes and vaccine immunogens that can be translated for the treatment and long-acting inhibition of HIV/AIDS. Though…
Robert Petrovich · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $1,303,146 — The protein expression facility (PEF) functions as a support group for the principal investigators at the NIEHS. Our focus is to provide the research groups with a means to generate the proteins they require so that they can perform their experiments. These projects range from generating enough o…
Ralph S Baric · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $136,800 — Abstract Zoonotic coronaviruses (CoV) are responsible for three major epidemics/pandemics in the 21st century, including Severe Acute Respiratory Coronavirus (SARS-CoV) in 2003 and the Middle East Respiratory coronavirus (MERS-CoV) in 2012. In Dec 2019, a third novel CoV designated SARS-CoV-2 emerge…
SABRA L. KLEIN · JOHNS HOPKINS UNIVERSITY · 2024 · $126,657 — Research Project 3 Summary There are insufficient data regarding the long-term humoral immune responses induced after SARS-CoV-2 infection. Our preliminary data indicate that there is variation in the magnitude and duration of antibody responses following SARS-CoV-2 infection. While IgG and IgA anti…
HUI-CHEN LU · TRUSTEES OF INDIANA UNIVERSITY · 2024 · $451,319 — SPECIFIC AIMS-Multiscale Imaging Core (MSIC) Addictive substances trigger plasticity at the molecular, cellular and circuit levels that manifest as persistent behavioral changes that may cause substance use disorders. Targeting these changes may lead to novel strategies for preventing or treating su…
David A. Hafler · YALE UNIVERSITY · 2024 · $473,661 — Elucidating mechanisms of novel mRNA nanoparticle and adenovirus-viral vector vaccine- induced T and B cell activation at the site of vaccination and lymph nodes is of critical importance. Studying patients with autoimmune disease treated with B cell depletion, we will perform a systems analysis to …
Mortimer Poncz · VERSITI BLOOD HEALTH, INC. · 2024 · $650,240 — ABSTRACT Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a complication of adenoviral (AdV)-based COVID-19 vaccination. Antibodies (Abs) against the 70-aa chemokine, platelet (Plt) factor 4 (PF4), have been noted in both VITT and in the related immune, prothrombotic disorder, heparin-i…
Mikyung Kim · DANA-FARBER CANCER INST · 2024 · $1,013,381 — SUMMARY – PROJECT 1 Neutralizing antibodies are a major component of vaccine-induced protective immunity. However, induction of broadly neutralizing antibody (bnAb) against the trimeric HIV-1 envelope (Env) spike protein gp160 continues to be a challenging goal. An effective vaccine must address the…
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2024 · $940,588 — SUMMARY – PROJECT 2 There are only a handful of sites on the HIV-1 envelope protein (Env) that represent regions of vulnerability for elicitation of broadly neutralizing antibodies (bnAbs). Four of these sites are associated with the gp120 subunit while one of the sites resides in the membrane-prox…
Shane P Crotty · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $781,696 — PROJECT SUMMARY – Project 1 COVID remains a major killer and disruptor worldwide. We made fundamental contributions to the understanding of COVID and T and B cell immune memory after SARS2 infection and COVID vaccines. Those studies predominantly examined human blood. In Project 1 we now aim to comp…
Kristina De Paris · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $195,770 — ABSTRACT The SARS-CoV-2 pandemic has resulted in enormous loss of life and in long-lasting health sequalae in a subset of convalescent patients. Little is known about the impact of SARS-CoV-2 infection on people with primary immune deficiency diseases (PIDD). There is also a lack of guidelines regar…
Samantha Kathleen Zepeda · UNIVERSITY OF WASHINGTON · 2024 · $43,560 — Abstract The outbreak of SARS-CoV-2 in late 2019 has resulted in the loss of over 6 million lives worldwide. Since then, there has been an intense focus on the development of vaccines and clinical treatments to increase the survivability of the disease caused by this virus. However, in nature other …
Lina A Shehadeh · MIAMI VA HEALTH CARE SYSTEM · 2024 — Myocarditis associated with COVID-19 infection, long COVID syndrome and COVID mRNA vaccination have emerged as urgent unmet clinical needs. Two recent studies involving >80-million persons including national healthcare databases from the US Department of Veteran Affairs confirmed that SARS-CoV-2 inf…
James Lai · TRULY TECHNOLOGIES LLC · 2024 · $55,000 — PROJECT SUMMARY/ABSTRACT Urine is an attractive biospecimen for point-of-care diagnostics because it can be collected in large quantities with noninvasive procedures. Urine-based lateral flow assays (LFAs) are low-cost devices suitable for point-of-care testing, particularly in low-resource settings…